We suspected that the reason may be that the IDH1 inhibitor treated, ivosidenib, mainly targets the mutated IDH1 or that pan-cancer cells may take advantage of alternative pathways for lipid synthesis during this inhibition. Here, IDH1 is linked to cancer.